X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CADILA HEALTHCARE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CADILA HEALTHCARE DISHMAN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.1 32.9 76.2% View Chart
P/BV x 3.3 6.5 51.3% View Chart
Dividend Yield % 0.7 0.7 92.1%  

Financials

 DISHMAN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE
Mar-17
DISHMAN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374460 81.4%   
Low Rs129305 42.3%   
Sales per share (Unadj.) Rs197.892.1 214.7%  
Earnings per share (Unadj.) Rs21.214.8 143.1%  
Cash flow per share (Unadj.) Rs34.718.5 187.9%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.80.8 95.0%  
Book value per share (Unadj.) Rs179.968.0 264.6%  
Shares outstanding (eoy) m80.691,023.74 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.2 30.6%   
Avg P/E ratio x11.925.8 46.0%  
P/CF ratio (eoy) x7.220.7 35.0%  
Price / Book Value ratio x1.45.6 24.9%  
Dividend payout %9.421.6 43.7%   
Avg Mkt Cap Rs m20,306391,581 5.2%   
No. of employees `0000.816.9 4.9%   
Total wages/salary Rs m5,35515,002 35.7%   
Avg. sales/employee Rs Th19,252.75,594.5 344.1%   
Avg. wages/employee Rs Th6,459.5890.1 725.7%   
Avg. net profit/employee Rs Th2,064.1899.9 229.4%   
INCOME DATA
Net Sales Rs m15,96194,295 16.9%  
Other income Rs m2651,286 20.6%   
Total revenues Rs m16,22695,581 17.0%   
Gross profit Rs m4,10319,036 21.6%  
Depreciation Rs m1,0913,750 29.1%   
Interest Rs m944450 209.9%   
Profit before tax Rs m2,33416,122 14.5%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m6241,289 48.4%   
Profit after tax Rs m1,71115,168 11.3%  
Gross profit margin %25.720.2 127.3%  
Effective tax rate %26.78.0 334.2%   
Net profit margin %10.716.1 66.6%  
BALANCE SHEET DATA
Current assets Rs m11,01860,223 18.3%   
Current liabilities Rs m9,51753,058 17.9%   
Net working cap to sales %9.47.6 123.8%  
Current ratio x1.21.1 102.0%  
Inventory Days Days11070 158.2%  
Debtors Days Days3588 39.5%  
Net fixed assets Rs m16,30472,984 22.3%   
Share capital Rs m1611,024 15.8%   
"Free" reserves Rs m12,90768,576 18.8%   
Net worth Rs m14,51669,600 20.9%   
Long term debt Rs m4,18924,684 17.0%   
Total assets Rs m29,805152,207 19.6%  
Interest coverage x3.536.8 9.4%   
Debt to equity ratio x0.30.4 81.4%  
Sales to assets ratio x0.50.6 86.4%   
Return on assets %8.910.3 86.8%  
Return on equity %11.821.8 54.1%  
Return on capital %17.517.9 97.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95221,280 23.3%   
Fx outflow Rs m69710,874 6.4%   
Net fx Rs m4,25510,406 40.9%   
CASH FLOW
From Operations Rs m2,78613,495 20.6%  
From Investments Rs m-1,529-29,103 5.3%  
From Financial Activity Rs m-94123,158 -4.1%  
Net Cashflow Rs m3167,556 4.2%  

Share Holding

Indian Promoters % 61.4 74.8 82.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.3 44.6%  
FIIs % 12.7 5.9 215.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 11.0 200.9%  
Shareholders   46,261 44,069 105.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  FDC LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; Banking Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS